Olga Maltseva Portfolio
Invests via Catalio Capital Management LP | Managed by George C. Petrocheilos, R. Jacob Vogelstein, Ph.D.
Invests via Catalio Capital Management LP
Managed by George C. Petrocheilos, R. Jacob Vogelstein, Ph.D.
Automatically Tracked
Olga Maltseva Profile
Olga Maltseva is a seasoned entrepreneur known for her innovative approach in the technology sector. With extensive experience in building and scaling tech startups, she has effectively merged strategic vision with operational excellence to drive growth. Her leadership has been pivotal in guiding companies through transformative stages, enabling them to navigate competitive landscapes successfully. Beyond her executive roles, Olga actively participates as an advisor, fostering emerging talent within the startup ecosystem while also contributing to investment dialogues focused on technology advancement and commercialization. She remains a significant figure within industry discussions centered around digital innovation.
Olga Maltseva is a seasoned entrepreneur known for her innovative approach in the technology sector. With extensive experience in building and scaling tech startups, she has effectively merged strategic vision with operational excellence to drive growth. Her leadership has been pivotal in guiding companies through transformative stages, enabling them to navigate competitive landscapes successfully. Beyond her executive roles, Olga actively participates as an advisor, fostering emerging talent within the startup ecosystem while also contributing to investment dialogues focused on technology advancement and commercialization. She remains a significant figure within industry discussions centered around digital innovation.
Investment Philosophy & Strategy
At the forefront of technology investment, Olga Maltseva embodies a vision for transformative growth through innovation. With an entrepreneurial mindset shaped by hands-on experience in building successful tech startups, she emphasizes strategic agility and operational refinement to capitalize on emerging opportunities. Her focus lies in identifying high-potential ventures that demonstrate scalability and disruptive capabilities within their respective markets. By championing new ideas and mentoring aspiring entrepreneurs, she nurtures a dynamic ecosystem conducive to technological advancement while facilitating productive dialogues around commercialization strategies. This holistic approach allows her to leverage both insights from her leadership journey and keen market awareness.
At the forefront of technology investment, Olga Maltseva embodies a vision for transformative growth through innovation. With an entrepreneurial mindset shaped by hands-on experience in building successful tech startups, she emphasizes strategic agility and operational refinement to capitalize on emerging opportunities. Her focus lies in identifying high-potential ventures that demonstrate scalability and disruptive capabilities within their respective markets. By championing new ideas and mentoring aspiring entrepreneurs, she nurtures a dynamic ecosystem conducive to technological advancement while facilitating productive dialogues around commercialization strategies. This holistic approach allows her to leverage both insights from her leadership journey and keen market awareness.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
56.5%
Gain -0.2%
Monthly
2.42%
Yearly
33.42%
Drawdown
19.95%
$562.73M
Equity
Holdings
$562.73M
Investment
$437.46M
$225.14M
Profit -$998,725.9
Realized
$99.88M
Unrealized
$125.26M
Dividends
$2.42M
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-0.2%
Profit
-$998,725.9
Win %
60%
This Week
Compared To Last Week
Gain
-3.02%
Profit
-$17.53M
Win %
60%
This Month
Compared to last month
Gain
-4.25%
Profit
-$24.95M
Win %
60%
This Year
Compared to last year
Gain
17.55%
Profit
$84.03M
Win %
68%
KPTI Karyopharm Therapeutics Inc.
+4.55%
+$305,221.06 
ELDN Eledon Pharmaceuticals Inc.
+2.46%
+$155,782.52 
HTFL HeartFlow, Inc.
+1.75%
+$173,542.84 
NAMS NewAmsterdam Pharma Co. N.V.
+1.53%
+$38,017.07 
DNTH Dianthus Therapeutics Inc.
+1.34%
+$756,415.8 
QURE uniQure N.V.
+1.33%
+$260,291.48 
MANE Veradermics Inc.
+1.13%
+$208,298.4 
MLYS Mineralys Therapeutics, Inc.
+1.09%
+$127,321.89 
CRVS Corvus Pharmaceuticals Inc.
+1.06%
+$133,789.95 
ABVX Abivax SA ADR
+0.94%
+$58,047.39 
GPCR Structure Therapeutics Inc.
+0.93%
+$111,089.87 
TYRA Tyra Biosciences, Inc.
+0.89%
+$18,503.37 
ASND Ascendis Pharma A/S
+0.87%
+$281,461.98 
CYTK Cytokinetics, Incorporated
+0.81%
+$137,920.64 
INCY Incyte Corporation
+0.79%
+$165,711.91 
RARE Ultragenyx Pharmaceutical Inc.
+0.61%
+$148,889.48 
FTH Faeth Therapeutics, Inc.
+0.57%
+$2,354.88 
BBIO BridgeBio Pharma, Inc.
+0.53%
+$185,766.02 
TARA Protara Therapeutics Inc.
+0.49%
+$11,600.48 
SEPN Septarna Inc.
+0.25%
+$23,548.8 
DFTX Definium Therapeutics, Inc.
+0.23%
+$103,798.4 
NTRA NATERA INC (Common Stock) – ticker 45E
+0.18%
+$34,389.89 
SNDX Syndax Pharmaceuticals Inc.
+0.14%
+$31,310.1 
BMY Bristol-Myers Squibb Company
+0.1%
+$25,243.62 
IMCR Immunocore Holdings plc American Depositary Receipt
0%
$0 
KALV KalVista Pharmaceuticals Inc.
0%
$0 
SLNO Soleno Therapeutics, Inc.
0%
$0 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
GILD Gilead Sciences Inc.
-2.94%
-$642,509.24 
GUTS Fractyl Health Inc.
-1.93%
-$82,927.18 
MGX Metagenomi, Inc.
-1.64%
-$10,579.86 
HYPR Hyperfine Inc.
-1.45%
-$18,744.58 
BSX Boston Scientific Corporation
-1.37%
-$179,590.8 
OM Outset Medical Inc.
-1.23%
-$5,913.95 
SUPN Supernus Pharmaceuticals Inc.
-1.03%
-$30,395.51 
PHAT Phathom Pharmaceuticals Inc.
-0.9%
-$23,859.96 
EW Edwards Lifesciences Corporation
-0.88%
-$107,732.21 
DYN Dyne Therapeutics Inc.
-0.3%
-$19,806.78 
IRON Disc Medicine Inc.
-0.2%
-$18,446.7 
ADPT Adaptive Biotechnologies Corporation
-0.09%
-$3,613.92 
ATAI AtaiBeckley Inc.
-0.07%
-$984.29 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 199 | Longs Won 111/199 55% | Profit Factor 3.63 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $4.66M |
| Average Win $2.8M | Best Trade (Jul 19) $46.95M | Sharpe Ratio -216.31 |
| Average Loss -$971,013.18 | Worst Trade (Jul 21) -$10.79M | Z-Score -0.96 (66.36%) |
| Commissions $0 | Avg. Trade Length 7m 1w 2d | Expectancy $1.13M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.21% |
| Consecutive Losing Trades | 579 | 521 | 463 | 406 | 348 | 290 | 232 | 174 | 116 | 58 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Olga Maltseva?
The largest contributions to the portfolio's profits come from the following stocks: BridgeBio Pharma, Inc - $22.82M, Structure Therapeutics Inc - $16.72M, Eli Lilly and Company - $16.14M, Regeneron Pharmaceuticals, Inc - $7.48M, and Dianthus Therapeutics Inc - $7.4M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Septarna Inc - $9M, MoonLake Immunotherapeutics - $5.58M, Veracyte Inc - $4.88M, LivaNova PLC - $3.6M, and Boston Scientific Corporation - $2.73M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Olga Maltseva's portfolio generate?
The portfolio generates substantial dividend income, with a total of $2.42M earned over time. The largest contributors to dividend income include Bristol-Myers Squibb Company - $982,708, Gilead Sciences Inc - $550,869.19, AbbVie Inc - $253,927.76, Eli Lilly and Company - $247,307.79, and Johnson & Johnson - $157,092. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Olga Maltseva's monthly returns?
Olga Maltseva's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Olga Maltseva's strategy be considered aggressive or moderate?
Olga Maltseva's strategy can be described as moderate. It balances growth potential with risk management, showing a willingness to accept some volatility while still maintaining a relatively structured and diversified approach.
Should beginners follow Olga Maltseva's strategy?
Olga Maltseva's strategy may be suitable for beginners, but with some caution. While the overall approach is not overly complex, it still involves a certain level of risk and variability. Beginners should be prepared for occasional fluctuations and ensure they understand the strategy before trying to follow it.
